AllSight
Companies · CRNC · Services-Prepackaged Software · Other events · Aug 26, 2026

Cerence repurchases $10M of convertible notes below par, trims debt opportunistically

$10M notes repurchasenew
92.75% of $10M principal, implying $725K below-par savings before accrued interest
Cerence Inc. (CRNC) — what happened, in plain English, and what it means versus what the market expected.

The filing introduces an unanticipated debt-reduction action, not an operating update. Cerence agreed to repurchase $10 million of its 1.50% convertible notes due 2028, and intends to cancel them. With no published consensus or prior guidance for this transaction, the relevant benchmark is the pre-filing assumption that the notes would remain outstanding until maturity or another refinancing event.

ItemFiling figure
Convertible notes repurchased$10.0 million principal
Cash price92.75% of principal
Implied cash purchase price$9.275 million, plus accrued interest
Implied discount to par$0.725 million, or 7.25%
Notes1.50% convertible senior notes due 2028

Cerence is buying back debt below face value. Paying 92.75 cents per dollar and retiring the notes reduces principal obligations by $10 million while requiring roughly $9.275 million of cash, before accrued interest. 〔0〕

The net read is modestly favorable but financially limited. The company captures an implied $725,000 discount and removes some future debt exposure, but the transaction is small in absolute terms and uses cash; the filing provides no information on remaining liquidity, total debt, or the accounting treatment of the gain. Relative to an expectation of no such transaction, it is a modest capital-structure positive rather than a major change to the investment picture.

Read the original 8-K on SEC EDGAR ↗
All CRNC filings, decoded →
Related companies in Services-Prepackaged Software
Latest across the market
DYDycom’s Q2 beats on EPS, but wireless delays blunt the upgradeSMMTSummit Therapeutics’ ivonescimab clears biliary-cancer OS bar, but data stay toplineANFAbercrombie & Fitch beats Q2 targets, raises guide—but tariffs inflate EPSCELCCelcuity submits REVTORPYK sNDA, opening PIK3CA-mutant label expansionBHVNBiohaven lands $400M Kv7 deal, but RISE3 data still decides opakalim’s valueMOVMovado beats Q2 estimates, but duty refunds mask part of margin surgeBrowse all companies, decoded →
Open live on AllSight — the whole market, decoded →
AllSight turns SEC filings into plain-English, neutral reads and objective market context. We explain what happened and how it lands versus expectations — we do not give investment advice or predict prices. Decoded straight from the filing; check it against the source.